ROYCE & ASSOCIATES LP - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 1 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$254,000
-64.1%
527,9000.0%0.00%
-66.7%
Q1 2019$707,000
+31.2%
527,900
+10.7%
0.01%
+20.0%
Q4 2018$539,000
-59.0%
476,9000.0%0.01%
-44.4%
Q3 2018$1,316,000
+136.7%
476,900
+206.1%
0.01%
+125.0%
Q2 2018$556,000155,8000.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q3 2023
NameSharesValueWeighting ↓
Broadfin Capital, LLC 1,048,642$3,219,0000.50%
Virtus ETF Advisers LLC 130,920$402,0000.35%
683 Capital Management, LLC 600,000$1,842,0000.16%
Tekla Capital Management LLC 859,322$2,638,0000.10%
DOW CHEMICAL CO /DE/ 65,000$200,0000.07%
Alambic Investment Management, L.P. 115,834$356,0000.05%
A.R.T. Advisors, LLC 262,896$807,0000.03%
Candriam S.C.A. 520,613$1,598,0000.03%
Man Group plc 1,674,341$5,140,0000.02%
Baker Brothers Advisors 935,000$2,870,0000.02%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders